Q-omics provides the consensus-scored GOLGA8J profile across patient tissues and cancer cell-line models. GOLGA8J expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, GOLGA8J is differentially expressed in 1, with the highest sampling consensus in THCA. Additionally, GOLGA8J RNA expression shows 6,685 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, THCA, and STAD as cancer lineages where GOLGA8J shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GOLGA8J — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GOLGA8J survival associations across molecular data types. GOLGA8J RNA expression shows survival associations in the most cancer types (13), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GOLGA8J RNA expression–survival associations across cancer types. High GOLGA8J expression shows unfavorable associations in MESO, KIRC, SKCM, HNSC and LIHC, but favorable associations in LGG. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for GOLGA8J RNA expression.
This table summarizes GOLGA8J tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for GOLGA8J. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GOLGA8J shows lower tumor expression in THCA. The THCA box plot shows higher GOLGA8J RNA expression in normal versus tumor tissue (log2 FC = −0.032, t-test p = .004).
This table shows molecular features associated with GOLGA8J in patient tissues and cancer cell lines. In patient samples, GOLGA8J shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, GOLGA8J RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia.
